Most, if not all, human diseases are caused by genetic changes. Although researchers now know the underlying genetic changes associated with respective diseases, functional validation of these changes is still crucial to directly attribute genotypic changes to phenotypic outcomes. In this project we will establish and in vivo platform for RNA editing based on the recently described CRISPR/Cas13 system. We will develop tools for inducible RNA editing, benchmark this system for in vivo use, and perform first proof of concept studies. The ultimate goal of this project is to generate new RNA editing technology, which will be distributed to the research community, to make it accessible for a broad use in different scientific disciplines.
My project is risky but could hold great promise for future applications in various disease models or even in therapeutic applications. The flexibility and the possibility to pursue risky projects by the Klaus Tschira Boost Fund will have tremendous value for successful execution. Additionally, it will boost our visibility on an international level and foster new collaborative relationships. I anticipate that the Klaus Tschira Boost Fund will also help us in connecting and distributing this technology to other researchers, building an international network around the technology and their users. I am particular excited about the possibility to join an Alumni network through the Klaus Tschira Boost fund for exchanging ideas and experiences.
... would like to be closer to nature. One dream would be to have a vineyard, where I could take care of the grapes and make my own wine.
Name: Dr. Darjus Tschaharganeh
Research field: Cancer Research
Institution: Helmholtz University Group / “Cell Plasticity and Epigenetic Remodeling” / German Cancer Research Center